STOCK TITAN

BlossomHill Therapeutics: Vivo reports 4.7% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

BlossomHill Therapeutics, Inc. (BLSM) is the issuer in an amended Schedule 13G reporting 1,493,740 shares beneficially owned by Vivo Innovation Fund II Holdings, L.P. and its general partner, Vivo Innovation II, LLC. Each reports ownership of 4.7% of the class. The shares are held of record by the fund, and both entities report sole voting and dispositive power over the same position. BlossomHill had 31,784,909 shares outstanding as of September 16, 2026.

Beneficially owned shares 1,493,740 shares Reported by both Vivo Innovation Fund II Holdings, L.P. and its general partner, Vivo Innovation II, LLC; held of record by the fund.
Percent of class 4.7% Reported by each reporting person.
Shares outstanding 31,784,909 shares BlossomHill shares outstanding as of September 16, 2026.
beneficially owned regulatory
"Amount beneficially owned: 1,493,740 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting power regulatory
"Sole voting power 1,493,740"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power regulatory
"Sole dispositive power 1,493,740"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BLSM shares does Vivo report beneficially owning?

Vivo Innovation Fund II Holdings, L.P. and its general partner, Vivo Innovation II, LLC, each report beneficial ownership of 1,493,740 BlossomHill common shares, or 4.7% of the class. The shares are held of record by the fund, so the two reports describe the same share position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





095130100

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents shares of common stock, par value $0.0001 per share (the "Common Stock") of BlossomHill Therapeutics, Inc. (the "Issuer"), which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P. The percent is based on 31,784,909 shares of the Issuer's Common Stock outstanding, as of September 16, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on September 18, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P. The percent is based on 31,784,909 shares of the Issuer's Common Stock outstanding, as of September 16, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 18, 2026.


SCHEDULE 13G



Vivo Innovation Fund II Holdings, L.P.
Signature:/s/ Gaurav Aggarwal
Name/Title:Gaurav Aggarwal/Managing Member of Vivo Innovation II, LLC, General Partner
Date:11/16/2026
Vivo Innovation II, LLC
Signature:/s/ Gaurav Aggarwal
Name/Title:Gaurav Aggarwal/Managing Member
Date:11/16/2026

Keep reading